New Migraine Drug Levadex Performs Well in Trial
Phase III clinical trials for Levadex, a new Migraine abortive medication are progressing well. Levadex, from MAP Pharmaceuticals, has been referred to as MAP004 previously. In a Phase III clinical trial at the Jefferson Headache Center in Philadelphia, participants who received Levadex experienced greater relief from pain, nausea, ... Read more












